Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Inducing destruction of specific mRNA using small interfering RNA (siRNA) is a powerful tool in analysis of protein function, but its use as a therapeutic modality has been limited by inefficient or impractical delivery systems. We have used siRNA incorporated into the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) for efficient in vivo siRNA delivery. In nude mice bearing i.p. ovarian tumors, nonsilencing siRNA tagged with the fluorochrome Alexa 555 was encapsulated into DOPC liposomes and shown to be taken up by the tumor as well as many major organs. Furthermore, DOPC-encapsulated siRNA targeting the oncoprotein EphA2 was highly effective in reducing in vivo EphA2 expression 48 hours after a single dose as measured by both Western blot and immunohistochemistry. Therapy experiments in an orthotopic mouse model of ovarian cancer were initiated 1 week after injection of either HeyA8 or SKOV3ip1 cell lines. Three weeks of treatment with EphA2-targeting siRNA-DOPC (150 microg/kg twice weekly) reduced tumor growth when compared with a nonsilencing siRNA (SKOV3ip1: 0.35 versus 0.70 g; P = 0.020; HeyA8: 0.98 versus 1.51 g; P = 0.16). When EphA2-targeting siRNA-DOPC was combined with paclitaxel, tumor growth was dramatically reduced compared with treatment with paclitaxel and a nonsilencing siRNA (SKOV3ip1: 0.04 versus 0.22 g; P < 0.001; HeyA8: 0.21 versus 0.84 g; P = 0.0027). These studies show the feasibility of siRNA as a clinically applicable therapeutic modality.

[1]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[2]  Patty J. Lee,et al.  Small Interfering RNA Targeting Heme Oxygenase-1 Enhances Ischemia-Reperfusion-induced Lung Apoptosis* , 2004, Journal of Biological Chemistry.

[3]  Alec,et al.  August 1 , 1964 .

[4]  K. Hirokawa,et al.  Overexpression of protein tyrosine kinases in human esophageal cancer. , 1997, Pathobiology : journal of immunopathology, molecular and cellular biology.

[5]  Mouldy Sioud,et al.  Gene silencing by systemic delivery of synthetic siRNAs in adult mice. , 2003, Journal of molecular biology.

[6]  G. Hortobagyi,et al.  Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Silver,et al.  Therapeutic potential of retroviral RNAi vectors , 2004, Expert opinion on biological therapy.

[8]  Sanyog Jain,et al.  Liposomes Modified with Cyclic RGD Peptide for Tumor Targeting , 2004, Journal of drug targeting.

[9]  F. Natt,et al.  siRNA relieves chronic neuropathic pain. , 2004, Nucleic acids research.

[10]  I. Fidler,et al.  Orthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in Mice , 1998, Cancer and Metastasis Reviews.

[11]  E. Pasquale,et al.  The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization , 2000, Oncogene.

[12]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[13]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[14]  J. G. Patton,et al.  siRNA therapeutics: big potential from small RNAs , 2005, Gene Therapy.

[15]  M. Kinch,et al.  EphA2 overexpression causes tumorigenesis of mammary epithelial cells. , 2001, Cancer research.

[16]  A. Flenniken,et al.  Distinct and overlapping expression patterns of ligands for Eph-related receptor tyrosine kinases during mouse embryogenesis. , 1996, Developmental biology.

[17]  D. Bostwick,et al.  Overexpression of the EphA2 tyrosine kinase in prostate cancer , 1999, The Prostate.

[18]  G. Hannon,et al.  Unlocking the potential of the human genome with RNA interference , 2004, Nature.

[19]  K. Taira,et al.  Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[21]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[22]  C. Schem,et al.  [Epithelial ovarian cancer]. , 2007, Therapeutische Umschau. Revue therapeutique.

[23]  David L. Lewis,et al.  Efficient delivery of siRNA for inhibition of gene expression in postnatal mice , 2002, Nature Genetics.

[24]  J. Bennett,et al.  Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. , 2003, Molecular vision.

[25]  A. Tari,et al.  Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. , 1999, The Journal of pharmacology and experimental therapeutics.

[26]  J. Biegel,et al.  ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. , 1997, Genomics.

[27]  S. Ashley,et al.  Systemic siRNA-Mediated Gene Silencing: A New Approach to Targeted Therapy of Cancer , 2004, Annals of surgery.

[28]  Ola Snøve,et al.  Many commonly used siRNAs risk off-target activity. , 2004, Biochemical and biophysical research communications.

[29]  C. Cepko,et al.  Electroporation and RNA interference in the rodent retina in vivo and in vitro , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Behr,et al.  Lipid‐mediated siRNA delivery down‐regulates exogenous gene expression in the mouse brain at picomolar levels , 2005, The journal of gene medicine.

[31]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  T. Hunter,et al.  cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases , 1990, Molecular and cellular biology.

[33]  Z. Hall.  Cancer , 1906, The Hospital.

[34]  C. Benz,et al.  Anti-HER2 immunoliposomes for targeted therapy of human tumors. , 1997, Cancer letters.

[35]  A. Sood,et al.  EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma , 2004, Clinical Cancer Research.

[36]  M. Kinch,et al.  Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer , 2004, Clinical & Experimental Metastasis.

[37]  Andrew D. Miller,et al.  Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. , 2004, Biochemistry.

[38]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[39]  John J Rossi,et al.  Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase , 2004, Nature Biotechnology.

[40]  P. S. St. John,et al.  ELK and LERK-2 in developing kidney and microvascular endothelial assembly. , 1996, Kidney international. Supplement.

[41]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[42]  Haibin Xia,et al.  siRNA-mediated gene silencing in vitro and in vivo , 2002, Nature Biotechnology.

[43]  P. Dobrzanski,et al.  Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist , 2004, Cancer Research.

[44]  C. Perez,et al.  Principles and Practice of Gynecologic Oncology , 1992 .

[45]  M. Kinch,et al.  Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1 , 2004, Cancer Gene Therapy.

[46]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[47]  Magdalena Zernicka-Goetz,et al.  Specific interference with gene function by double-stranded RNA in early mouse development , 2000, Nature Cell Biology.

[48]  S. Ashley,et al.  RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. , 2003, Biochemical and biophysical research communications.

[49]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[50]  Gong Yang,et al.  Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer , 2003, Oncogene.

[51]  R. Bernards,et al.  Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.

[52]  A. Reith,et al.  Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap retroviral insertion. , 1996, Oncogene.

[53]  C. Miller,et al.  Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. , 1998, Biochemistry.

[54]  Douglas S. Conklin,et al.  Gene expression: RNA interference in adult mice , 2002, Nature.

[55]  S. Ashley,et al.  EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma , 2004, Oncogene.

[56]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[57]  M. Manns,et al.  Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA , 2015 .

[58]  C. Bucana,et al.  Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. , 2004, Gynecologic oncology.